Pharmacogenetics and Schizophrenia

Adriana Elena Foster, Del D. Miller, Peter F Buckley

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

The wide interindividual variability in clinical response and tolerability of antipsychotic medications has led investigators to postulate that these variabilities may be under genetic control. Although not always consistent, there are promising indications from emergent pharmacogenetic studies that efficacy of antipsychotic medications for the various symptom domains of psychopathology in schizophrenia may be genetically regulated. This is an encouraging approach. Moreover, there are also suggestive findings that the side-effect profiles of second-generation antipsychotic medications and their propensity to cause weight gain and glucose and lipid abnormalities as well as tardive dyskinesia may be related to pharmacogenetic factors in this patient population. Ultimately, such approaches could drive choices of antipsychotic medication based on the likelihood of clinical response and development of side effects in light of a particular patient's genetic profile. In the future, this targeted approach (personalized medicine) may become informative for clinicians choosing an antipsychotic medication for an individual patient with schizophrenia.

Original languageEnglish (US)
Pages (from-to)975-993
Number of pages19
JournalClinics in Laboratory Medicine
Volume30
Issue number4
DOIs
StatePublished - Dec 1 2010

Fingerprint

Pharmacogenetics
Antipsychotic Agents
Schizophrenia
Precision Medicine
Psychopathology
Weight Gain
Medicine
Research Personnel
Lipids
Glucose
Population

Keywords

  • Antipsychotics
  • Personalized medicine
  • Pharmacogenetics
  • Schizophrenia

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Foster, A. E., Miller, D. D., & Buckley, P. F. (2010). Pharmacogenetics and Schizophrenia. Clinics in Laboratory Medicine, 30(4), 975-993. https://doi.org/10.1016/j.cll.2010.07.010

Pharmacogenetics and Schizophrenia. / Foster, Adriana Elena; Miller, Del D.; Buckley, Peter F.

In: Clinics in Laboratory Medicine, Vol. 30, No. 4, 01.12.2010, p. 975-993.

Research output: Contribution to journalReview article

Foster, AE, Miller, DD & Buckley, PF 2010, 'Pharmacogenetics and Schizophrenia', Clinics in Laboratory Medicine, vol. 30, no. 4, pp. 975-993. https://doi.org/10.1016/j.cll.2010.07.010
Foster, Adriana Elena ; Miller, Del D. ; Buckley, Peter F. / Pharmacogenetics and Schizophrenia. In: Clinics in Laboratory Medicine. 2010 ; Vol. 30, No. 4. pp. 975-993.
@article{9c00864b8ce5482c9b47844e76530c57,
title = "Pharmacogenetics and Schizophrenia",
abstract = "The wide interindividual variability in clinical response and tolerability of antipsychotic medications has led investigators to postulate that these variabilities may be under genetic control. Although not always consistent, there are promising indications from emergent pharmacogenetic studies that efficacy of antipsychotic medications for the various symptom domains of psychopathology in schizophrenia may be genetically regulated. This is an encouraging approach. Moreover, there are also suggestive findings that the side-effect profiles of second-generation antipsychotic medications and their propensity to cause weight gain and glucose and lipid abnormalities as well as tardive dyskinesia may be related to pharmacogenetic factors in this patient population. Ultimately, such approaches could drive choices of antipsychotic medication based on the likelihood of clinical response and development of side effects in light of a particular patient's genetic profile. In the future, this targeted approach (personalized medicine) may become informative for clinicians choosing an antipsychotic medication for an individual patient with schizophrenia.",
keywords = "Antipsychotics, Personalized medicine, Pharmacogenetics, Schizophrenia",
author = "Foster, {Adriana Elena} and Miller, {Del D.} and Buckley, {Peter F}",
year = "2010",
month = "12",
day = "1",
doi = "10.1016/j.cll.2010.07.010",
language = "English (US)",
volume = "30",
pages = "975--993",
journal = "Clinics in Laboratory Medicine",
issn = "0272-2712",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Pharmacogenetics and Schizophrenia

AU - Foster, Adriana Elena

AU - Miller, Del D.

AU - Buckley, Peter F

PY - 2010/12/1

Y1 - 2010/12/1

N2 - The wide interindividual variability in clinical response and tolerability of antipsychotic medications has led investigators to postulate that these variabilities may be under genetic control. Although not always consistent, there are promising indications from emergent pharmacogenetic studies that efficacy of antipsychotic medications for the various symptom domains of psychopathology in schizophrenia may be genetically regulated. This is an encouraging approach. Moreover, there are also suggestive findings that the side-effect profiles of second-generation antipsychotic medications and their propensity to cause weight gain and glucose and lipid abnormalities as well as tardive dyskinesia may be related to pharmacogenetic factors in this patient population. Ultimately, such approaches could drive choices of antipsychotic medication based on the likelihood of clinical response and development of side effects in light of a particular patient's genetic profile. In the future, this targeted approach (personalized medicine) may become informative for clinicians choosing an antipsychotic medication for an individual patient with schizophrenia.

AB - The wide interindividual variability in clinical response and tolerability of antipsychotic medications has led investigators to postulate that these variabilities may be under genetic control. Although not always consistent, there are promising indications from emergent pharmacogenetic studies that efficacy of antipsychotic medications for the various symptom domains of psychopathology in schizophrenia may be genetically regulated. This is an encouraging approach. Moreover, there are also suggestive findings that the side-effect profiles of second-generation antipsychotic medications and their propensity to cause weight gain and glucose and lipid abnormalities as well as tardive dyskinesia may be related to pharmacogenetic factors in this patient population. Ultimately, such approaches could drive choices of antipsychotic medication based on the likelihood of clinical response and development of side effects in light of a particular patient's genetic profile. In the future, this targeted approach (personalized medicine) may become informative for clinicians choosing an antipsychotic medication for an individual patient with schizophrenia.

KW - Antipsychotics

KW - Personalized medicine

KW - Pharmacogenetics

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=77956501308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956501308&partnerID=8YFLogxK

U2 - 10.1016/j.cll.2010.07.010

DO - 10.1016/j.cll.2010.07.010

M3 - Review article

C2 - 20832661

AN - SCOPUS:77956501308

VL - 30

SP - 975

EP - 993

JO - Clinics in Laboratory Medicine

JF - Clinics in Laboratory Medicine

SN - 0272-2712

IS - 4

ER -